Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)CAB and Oryzon establish primary and ...

CStone Pharmaceuticals ('CStone', HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter ...

An expanded clinical trial that tested an experimental stem cell treatment for blinding cornea injuries found the treatment ...

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A ...

We recently published a list of 12 Penny Stocks with Insider Buying in 2025. In this article, we are going to take a look at ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

A decade of studies from labs around the world provide a growing evidence base that increasing the power of the brain's gamma rhythms could help fight Alzheimer's, and perhaps other, neurological ...

A new stem cell therapy, CALEC, has demonstrated a 92% success rate in regenerating corneas and restoring vision. This ...

According to the terms of the deal, Blackstone will acquire a 60 percent stake while CMIC HD will retain the remaining 40 percent stake in the company.

A new computational tool allows researchers to understand how the diverse cell types of the human body are made during ...